Fibrinolytic and Haemostatic Responses to Desamino-D-Arginine Vasopressin (DDAVP) Administered by Intravenous and Subcutaneous Routes in Healthy Subjects

I R MacGregor; E M Roberts; C V Prowse; A F Broomhead; M Ozolins; P Litka

doi:10.1055/s-0038-1642561

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 59(01): 034-039
DOI: 10.1055/s-0038-1642561

Review Article

Schattauer GmbH Stuttgart

Fibrinolytic and Haemostatic Responses to Desamino-D-Arginine Vasopressin (DDAVP) Administered by Intravenous and Subcutaneous Routes in Healthy Subjects

I R MacGregor

¹The H.Q. Unit Laboratory, The Frythe, Welwyn, Herts, UK

,

E M Roberts

¹The H.Q. Unit Laboratory, The Frythe, Welwyn, Herts, UK

,

C V Prowse

²Scottish National Blood Transfusion Service and S-E Scotland Blood Transfusion Service, The Frythe, Welwyn, Herts, UK

,

A F Broomhead

³Edinburgh and Smith Kline and French Research Ltd, The Frythe, Welwyn, Herts, UK

,

M Ozolins

³Edinburgh and Smith Kline and French Research Ltd, The Frythe, Welwyn, Herts, UK

,

P Litka

³Edinburgh and Smith Kline and French Research Ltd, The Frythe, Welwyn, Herts, UK

› Author Affiliations

Abstract

PDF Download

Summary

DDAVP was administered at 0.4 ug kg⁻¹ by intravenous (i. v.) and subcutaneous (s.c.) routes to 6 healthy subjects in a double blind crossover study. Both study treatments were well tolerated. Flushing occurred after both treatments but was more prominent after i.v. than after s.c. DDAVP. Mild transient local discomfort at the s.c. injection site occurred in 5 of 6 subjects. The mean peak factor VIII (FVIII) response was 369% and 247% of baseline after i.v. and s.c. DDAVP respectively and the maximum increase in FVIII occurred earlier with the i.v. route. Changes in FVIII antigen (FVIII: Ag) and von Willebrand factor antigen (vWF: Ag) were also monitored. Tissue-type plasminogen activator (t-PA) activity measured by a chromogenic assay employing soluble fibrin had a median peak value of 2.9 IU ml⁻¹ at 20 min after i.v. and of 1.9 IU ml⁻¹ at 60 min after s.c. DDAVP. t-PA antigen was a Iso incasiued so that die specific activity uf ciiculaliiig t-PA could be determined. Preinjection median values of 14,650 and 13,700 IU mg⁻¹ increased to peak median values of 236,200 IU mg⁻¹ at 20 min after i.v. and 202,400 IU mg⁻¹ at 60 min after s.c. DDAVP. Plasminogen activator inhibitor (PAI) activity fell following DDAVP and became undetectable in some subjects during the sampling period. The ratio of maximum fibrinolytic response was similar to the ratio of maximum haemostatic responses obtained by two routes of injection. Our results indicate that s.c. DDAVP might successfully replace i.v. DDAVP in several applications such as confirmation of haemostatic or fibrinolytic responsiveness in patient groups; for obtaining FVIII enriched plasma; as well as its obvious potential usefulness in home treatment of haemophilia A and von Willebrand’s disease.

Key words

DDAVP - Fibrinolytic - Tissue plasminogen activator - Plasminogen activator inhibitor - Factor VIII

PDF (505 kb)

References

References
1 Richardson DW, Robinson AG. Desmopressin. Ann Int Med 1985; 103: 228-239
2 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of hemophilia and von Willebrands disease. Lancet 1977; 1: 869-872
3 Nilsson IM, Holmberg L, Aberg M, Vilhardt H. The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrands disease. Scand J Haematol 1980; 24: 351-360
4 Ludlam CA, Peake IR, Allen N, Davies BL, Furlong RA, Bloom AL. Factor VIII and fibrinolytic response to dcsamino-D-argininc vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand’s disease. Br. J Haematol 1980; 45: 499-511
5 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of haemostasis. Prog Haemostas Thromb (in press);
6 Prowse CV, Ludlam CA. DDAVP; mechanism of action and clinical use. In Factor VIII and von Willebrand Factor 2. Segatchian MJ, Savidge GF. (Eds) CRC Press (in press);
7 de Sio L, Mariani G, Muzzucconi MG, Chistolini A, Tirindelli MC, Mandelli F. Comparison between subcutaneous and intravenous DDAVP in mild and moderate haemophilia A. Thromb Haemostas 1985; 54: 387-389
8 Köhler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemostas 1986; 55: 108-111
9 Prowse CV, Farrugia A, Boulton FE, Tucker J, Ludlam CA, Mc Laren M, Belch JJ F, Prentice CR M, Dawes J, MacGregor IR. A comparative study using immunological and biological assays of the haemostatic responses to DDAVP infusion, venous occlusion and exercise in normal men. Thromb Haemostas 1984; 51: 110-114
10 Mac Gregor IR, Prowse CV. Tissue plasminogen activator in human plasma measured by radioimmunoassay. Thromb Res 1983; 31: 461-474
11 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-485
12 Prowse CV, Hornsey V, Mc Kay G, Waterston Y. Room temperature, microtray chromogenic assay of factor VIII :C. Vox Sang 1986; 50: 21-25
13 Griffin BD, Micklem LR, Mc Cann M, James K, Pepper DS. The production and characterisation of a panel of 10 murine monoclonal antibodies to human procoagulant factor VIII. Thromh Haemostas 1986; 55: 40-46
14 Hornsey VS, Griffin BD, Pepper DS, Micklem LR, Prowse CV. Immunoaffinity purification of factor VIII complex. Thromh Haemostas 1987; 57: 102-105
15 Laurell CB. Electroimmunoassay. Scand I Clin Lab Invest 1972; 29 S124 21-37
16 Farrugia A. Studies on the procurement of blood coagulation factor VIII. PhD Thesis. University of Edinburgh; 1984
17 Gornall AG, Bardawill CJ, David MM. Determination of serum proteins bv means of the Biuret reaction. J Biol Chem 1949; 177: 751-766
18 Gaffney PI, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
19 Verstraete M, Bounameaux H, de Cock F, van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506-512
20 Wiman B, Mellbring G, Ranby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-288
21 Verheijen JH, Chang GT G, Kluft K. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
22 Booth NA, Mac Gregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from human endothelial cells: purification and partial characterisation. Fur J Biochem 1987; 165: 595-600
23 d’Angelo A, Kluft C, Verheijen JH, Rijken DC, Mozzi E, Mannucci A. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin invest 1985; 15: 308-312
24 Brommer EJ P, Barrett-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalckamp MA D H. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients – analysis of responders and non-responders. Thromb Haemostas 1982; 48: 156-161
25 Mikaelsson M, Nilsson IM, Vilhardt H, Wiechel B. Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue. Transfusion 1982; 22: 229-233